Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
LLY compared with VRXA: revenue, margins and what each company keeps, and the suppliers and customers both name
LLY
ELI Lilly & Co
Change
Mkt cap
Revenue
Revenue
VRXA
Veraxa Biotech AG - Post de-SPAC
Change
Mkt cap
Revenue
Revenue
vs
Compare
LLY
ELI Lilly & Co
vs
VRXA
Veraxa Biotech AG - Post de-SPAC
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
LLY
ELI Lilly & Co
Change
1,407.25
▼
−0.27%
· post 1,416.42
Mkt cap
$1.3T
Revenue
$24.4B
Q3 FY26
Revenue
$65.2B
FY25
VRXA
Veraxa Biotech AG - Post de-SPAC
Change
1.16
▲
+12.53%
· post 0.99
Closed
Nov 3 '26
Mkt cap
$14.9M
Revenue
—
Revenue
—
vs
Compare
Closed
Nov 3 '26
LLY
ELI Lilly & Co
vs
VRXA
Veraxa Biotech AG - Post de-SPAC
1,407.25
▼
−0.27%
post 1,416.42
Price
1.16
▲
+12.53%
post 0.99
$1.3T
Mkt cap
$14.9M
Q3 FY26
$24.4B
Revenue
—
FY25
$65.2B
Revenue
—
Change
Change
LLY
1,407.25
▼
−0.27%
vs
VRXA
1.16
▲
+12.53%
Closed
Nov 3 '26
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
LLY, solid
VRXA, dashed
Supply-chain overlap
Revenue flow
VRXA: latest quarter not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only LLY
29
MCK
McKesson
customer
CAH
Cardinal Health
customer
VEEV
Veeva Systems
supplier
UTHR
United Therapeutics
customer
25 more · LLY chain
›
Shared
0
No disclosed counterparties: VRXA.
Only VRXA
0
None
Role chip = supplier or customer
Source: SEC EDGAR